Seminars in Hematology
Volume 45, Issue 2 , Pages 71-74 , April 2008

Monoclonal Antibodies in Lymphoma: The First Decade

  • Brian K. Link

      Affiliations

    • Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA.
    • Corresponding Author InformationAddress correspondence to Brian K. Link, MD, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, 200 Hawkins Dr, C32 GH, Iowa City, IA 52242.
    • ,
  • Jonathan W. Friedberg

      Affiliations

    • James P. Wilmot Cancer Center, University of Rochester, Rochester, NY.

References 

  1. Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link B Kl. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol. 2005;23:5019–5026
  2. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TPI. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23:8447–8452
  3. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006;24:1582–1599
  4. Sacchi S, Pozzi S, Marcheselli L, Bari A, Luminari S, Angrilli F, et al. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer. 2007;109:2077–2082
  5. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–3732
  6. Marcus RE, Solal-Celigny P, Imrie K, Cunningham D, Flores E, Catalano J, et al. MabThera (rituximab) plus cyclophosphamide, vincristine and prednisone (CVP) chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkin’s lymphoma (NHL). Blood. 2006;108:146a
  7. Salles GA, Foussard C, Mounier Nl. Rituximab added to αIFN+CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: First analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients. Blood. 2004;104:160;(abstr)
  8. Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25:1986–1992
  9. Forstpointner R, Dreyling M, Repp R, Bock HP, Repp R, Wandt H, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:3064–3071
  10. Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis. J Natl Cancer Inst. 2007;99:706–714
  11. Coiffier B, Lepage E, Herbrecht R, Briere J, Tilly H, et al. Rituximab plus CHOP is superior to CHOP alone in elderly patients with DLBCL (Interim results of a randomized GELA study). Blood. 2000;96:223a;(abstr)
  12. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242
  13. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027–5033
  14. Friedberg JW, Kho ME, Lepisto EM. Evolution of rituximab as “standard” therapy in patients with newly diagnosed follicular, mantle cell and diffuse large B cell non-Hodgkin’s lymphoma in 5 United States Comprehensive Cancer Centers: An analysis from the National Comprehensive Cancer Network (NCCN) NHL outcomes project. Blood. 2004;104:1391a
  15. Friedberg JW, Huang J, Dillon H. Initial therapeutic strategy in follicular lymphoma: An analysis from the National LymphoCare study. J Clin Oncol. 2006;24:7527a
  16. Kocs D, Fendrick AM. Effect of off-label use of oncology drugs on pharmaceutical costs: The rituximab experience. Am J Manag Care. 2003;9:393–400
  17. Zelenetz AD. Will radioimmunotherapy survive?. Clin Adv Hematol Oncol. 2007;5:782–784

 J.W.F. is supported in part by a career development award from the National Cancer Institute (CA-102216).

PII: S0037-1963(08)00006-1

doi: 10.1053/j.seminhematol.2008.02.005

Seminars in Hematology
Volume 45, Issue 2 , Pages 71-74 , April 2008

Article Tools